May 30 2020
A proposal for a new clinical trial with a wide spectrum anti-viral called “isoquercetin” has been submitted to Health Canada by Pharmascience Inc. in partnership with the Montreal Clinical Research Institute (MCRI)/Institut de Recherches Cliniques de Montréal (IRCM) and International Consortium on Anti-Virals (ICAV). The trial targets patients hospitalized with mild to moderate COVID-19.
Dr Chrétien’s research team at MRCI/IRCM, in collaboration with the National Microbiology Laboratory in Winnipeg, has already demonstrated that isoquercetin is effective against the Ebola and Zika viruses in animals and against the SARS CoV-2 virus in vitro.
Dr. Jeremy Carver and the ICAV drug development team is providing expert support for this study on the efficacy of this naturally-occurring compound that is present in most people’s diet, for example in onions.